User Image Cart Icon 0 Search Image

Sulfonylureas

  1. Sulfonylureas
  2. Sulfonylureas in NIDDM
  3. Sulfonylureas.
  4. Sulfonylureas
  5. Sulfonylureas Why, Which, and How?
  6. Sulfonylureas and Sulfonylthioureas.
  7. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials
  8. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations
  9. State of the art paper Sulfonylureas and their use in clinical practice
  10. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin
  11. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
  12. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis
  13. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
  14. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations
  15. Individual sulfonylureas and serious hypoglycemia in older people
  16. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.
  17. Glucose, Sulfonylureas, and Neurotransmitter Release: Role of ATP-Sensitive K+ Channels
  18. Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas: A GoDARTs Study
  19. Rates of hypoglycemia in users of sulfonylureas
  20. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin
  21. The pharmacology of sulfonylureas
  22. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells.
  23. Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
  24. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K (ATP) channels.
  25. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational …
  26. Mortality risk among sulfonylureas: a systematic review and network meta-analysis
  27. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas
  28. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with …
  29. The place of sulfonylureas in the therapy for type 2 diabetes mellitus
  30. Mechanisms of the glycaemic effects of sulfonylureas
  31. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies
  32. Loss‐of‐function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go‐DARTS study
  33. Extrapancreatic effects of sulfonylureas—a comparison between glimepiride and conventional sulfonylureas
  34. Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus
  35. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
  36. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with …
  37. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
  38. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic β cells
  39. Tissue-specific effects of sulfonylureas: lessons from studies of cloned KATP channels
  40. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies
  41. Sulfonylureas: a new look at old therapy
  42. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events
  43. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
  44. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke
  45. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with …
  46. Antidiabetic sulfonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels.
  47. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young
  48. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta‐analysis
  49. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
  50. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus
  51. sulfonylureas differ in effects on ischemic preconditioning—is it time to retire glyburide?
  52. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas
  53. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider
  54. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.
  55. Sulfonylureas, ATP-sensitive K+ channels, and cellular K+ loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle.
  56. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial
  57. … or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
  58. Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and …
  59. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
  60. Head‐to‐head comparison of dipeptidyl peptidase‐IV inhibitors and sulfonylureas–a meta‐analysis from randomized clinical trials
  61. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
  62. Pancreatic β-cell K ATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
  63. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction
  64. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic β-cell line, MIN6
  65. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes
  66. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas
  67. Combining sulfonylureas and other oral agents
  68. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets
  69. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas
  70. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with …
  71. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
  72. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta …
  73. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic β-cells
  74. Sulfonimidamide Analogs of Oncolytic Sulfonylureas,1
  75. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on!
  76. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!
  77. Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia
  78. Hypoglycemia in hospitalized patients treated with sulfonylureas
  79. Sulfonylureas have antifungal activity and are potent inhibitors of Candida albicans acetohydroxyacid synthase
  80. Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor
  81. Defining a binding pocket for sulfonylureas in ATP‐sensitive potassium channels
  82. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)
  83. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas
  84. Antidiabetic sulfonylureas: localization of binding sites in the brain and effects on the hyperpolarization induced by anoxia in hippocampal slices
  85. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
  86. … in KCNJ11-Related Neonatal Diabetes Is Impaired in Children With DEND-Associated Mutations and May Be Improved by Early Treatment With Sulfonylureas
  87. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide
  88. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record–based study
  89. Monotoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas
  90. Anti-diabetic activity of Tinospora cordifolia (Willd.) in streptozotocin diabetic rats; does it act like sulfonylureas?
  91. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies
  92. Sulfonylureas and risk of falls and fractures: a systematic review
  93. … detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
  94. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population‐based cohort study
  95. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas
  96. Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes
  97. Long-term effects of a diet loosely restricting carbohydrates on HbA1c levels, BMI and tapering of sulfonylureas in type 2 diabetes: a 2-year follow-up study
  98. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
  99. Cardiovascular effects of conventional sulfonylureas and glimepiride
  100. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A
  101. ATP-sensitive K+ channels that are blocked by hypoglycemia-inducing sulfonylureas in insulin-secreting cells are activated by galanin, a hyperglycemia-inducing …
  102. Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C.
  103. Sulfonylureas: background and development of the field.
  104. All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides
  105. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas
  106. Pro-and antiarrhythmic actions of sulfonylureas: mechanistic and clinical evidence
  107. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
  108. Effects of sulfonylureas on tumor growth: a review of the literature
  109. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: a combined virtual screening and biological assay approach
  110. Preparation of Unsymmetrical Sulfonylureas from N,N’-Sulfuryldiimidazoles
  111. Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors
  112. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications
  113. Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex
  114. Multiple resistance to sulfonylureas and imidazolinones conferred by an acetohydroxyacid synthase gene with separate mutations for selective resistance
  115. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides‐induced atrophy in skeletal muscle
  116. Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe?
  117. Quantitative effects of glucose, sulfonylureas, salicylate, and indole-3-acetic acid on the secretion of insulin activity into pancreatic venous blood
  118. Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients.
  119. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus
  120. Creation and characterization of a mitochondrial DNA-depleted pancreatic beta-cell line: impaired insulin secretion induced by glucose, leucine, and sulfonylureas.
  121. Biguanides and sulfonylureas as combination therapy in NIDDM
  122. The benefits and risks of DPP 4‐inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial
  123. Monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients: a systematic review and meta-analysis
  124. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas
  125. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case‐control study
  126. Sulfonylureas: a new class of cancer chemotherapeutic agents
  127. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
  128. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide
  129. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro
  130. Molecular basis of resistance to sulfonylureas in Papaver rhoeas
  131. … of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide
  132. Sulfonylureas and cardiovascular safety: the final verdict?
  133. Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 …
  134. Synthesis of some sulfonamides, disubstituted sulfonylureas or thioureas and some structurally related variants. A class of promising antitumor agents
  135. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis
  136. Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia
  137. Sulfonylureas and the risk of myocardial infarction
  138. Design, synthesis and herbicidal activity study of aryl 2, 6-disubstituted sulfonylureas as potent acetohydroxyacid synthase inhibitors
  139. Synthetic homoserine lactone-derived sulfonylureas as inhibitors of Vibrio fischeri quorum sensing regulator
  140. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography–ion-trap tandem mass spectrometry and library searching
  141. Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
  142. ATP-modulated K+ channels sensitive to antidiabetic sulfonylureas are present in adenohypophysis and are involved in growth hormone release.
  143. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding sulfonylureas, biguanides and insulin.
  144. Cardiovascular benefits of acarbose vs sulfonylureas in patients with type 2 diabetes treated with metformin
  145. High-performance liquid chromatographic determination of sulfonylureas in soil and water
  146. Effects of thiazolidinediones and sulfonylureas in patients with diabetes
  147. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction
  148. Metformin’s effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas
  149. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits
  150. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6. x subtypes
  151. Glucose both inhibits and stimulates insulin secretion from isolated pancreatic islets exposed to maximally effective concentrations of sulfonylureas
  152. Nonenzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylureas
  153. Appraisal of the extrapancreatic actions of sulfonylureas
  154. … module of direct analysis in real time mass spectrometry for sensitive and high-throughput screening of illegally adulterated sulfonylureas in antidiabetic health-care …
  155. Design, synthesis and SAR study of novel sulfonylureas containing an alkenyl moiety
  156. Acetohydroxyacid synthase from Mycobacterium avium and its inhibition by sulfonylureas and imidazolinones
  157. Comparative safety of dipeptidyl peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes
  158. Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients-knowledge and self-management
  159. Fast capillary electrophoresis—ion spray mass spectrometric determination of sulfonylureas
  160. Cost-effectiveness analysis of metformin+ dipeptidyl peptidase-4 inhibitors compared to metformin+ sulfonylureas for treatment of type 2 diabetes
  161. Progressing from metformin to sulfonylureas or meglitinides
  162. … of a sulfonylurea-receptor-like protein in plants: modulation of stomatal movements and guard cell potassium channels by sulfonylureas and potassium channel …
  163. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry
  164. Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor
  165. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study
  166. Influence of pH and irradiation wavelength on the photochemical degradation of sulfonylureas
  167. The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels
  168. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas
  169. Sodium-glucose co-transporter 2 inhibitors compared with sulfonylureas in patients with type 2 diabetes inadequately controlled on metformin: a meta-analysis of …
  170. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up study
  171. QSAR and 3D‐QSAR analysis of structurally diverse ALS inhibitors: sulfonylureas and triazolopyrimidine‐2‐sulfonamides
  172. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials
  173. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus
  174. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death
  175. Reduced Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas: A Case-Control Study
  176. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients
  177. Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations
  178. Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas
  179. Influence of straw management, nitrogen fertilization and dosage rates on the dissipation of five sulfonylureas in soil
  180. Identification of sulfonylureas in serum by electrospray mass spectrometry
  181. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas
  182. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy
  183. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas
  184. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients
  185. Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism
  186. Sulfonylureas inhibit cytokine-induced eosinophil survival and activation
  187. Binding of sulfonylureas to serum proteins
  188. Effects of sulfonylureas on peroxisome proliferator-activated receptor γ activity and on glucose uptake by thiazolidinediones
  189. Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (Imidazolylbiphenylyl) …
  190. The infamous, famous sulfonylureas and cardiovascular safety: much ado about nothing?
  191. Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to its receptors in target cells
  192. The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes
  193. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus
  194. Serious hypoglycemia and use of warfarin in combination with sulfonylureas or metformin
  195. CYP2C9* 2 allele increases risk for hypoglycemia in POR* 1/* 1 type 2 diabetic patients treated with sulfonylureas
  196. Sulfonylureas: basic aspects and clinical uses
  197. Intracellular targets for antidiabetic sulfonylureas and potassium channel openers
  198. Adenosine triphosphate levels of mammalian pancreatic B cells after stimulation with glucose and hypoglycemic sulfonylureas
  199. Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino) alkyl] benzoic acids
  200. Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug …
  201. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in …
  202. Sulfonylureas blockade of neural and cardiac HERG channels
  203. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics
  204. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis
  205. The Effect of Insulin Treatment on HbA1c, Body Weight and Lipids in Type 2 Diabetic Patients with Secondary-Failure to Sulfonylureas.
  206. Photochemistry of sulfonamides and sulfonylureas: A contribution to the problem of light‐induced dermatoses
  207. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles
  208. Blockade of the antinociception induced by diclofenac, but not of indomethacin, by sulfonylureas and biguanides
  209. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor
  210. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: a cohort study
  211. Hydrogen‐isotope exchange (HIE) reactions of secondary and tertiary sulfonamides and sulfonylureas with iridium (I) catalysts
  212. The TOSCA. IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes
  213. Hypoglycemia induced by antidiabetic sulfonylureas
  214. Sulfonylureas: do we need to introspect safety again?
  215. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use
  216. How do sulfonylureas approach their receptor in the B-cell plasma membrane?
  217. Design, synthesis and bioactivity of novel herbicides targeted ALS (VII): Quantitative structure‐activity relationships of herbicidal sulfonylureas
  218. Comparison of two sulfonylureas with high and low myocardial KATP channel affinity on myocardial infarct size and metabolism in a rat model of type 2 …
  219. Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes
  220. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus
  221. The hypoglycemic sulfonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting carnitine palmitoyltransferase.
  222. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone
  223. Antidiabetic effects of dipeptidyl peptidase–IV inhibitors and sulfonylureas in streptozotocin-nicotinamide–induced mildly diabetic mice
  224. Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics
  225. Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas
  226. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction
  227. Evaluation of the in vitro and intracellular efficacy of new monosubstituted sulfonylureas against extensively drug-resistant tuberculosis
  228. Misunderstandings and controversies about the insulin-secreting properties of antidiabetic sulfonylureas
  229. Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3
  230. Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta‐analysis of randomized controlled trials
  231. Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: A mechanistic study
  232. Interaction of sulfonylureas with pancreatic β-cells: a study with glyburide
  233. Effects of sulfonylureas on mitochondrial ATP‐sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy
  234. Glucocrinology of modern sulfonylureas: Clinical evidence and practice-based opinion from an international expert group
  235. Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma
  236. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide
  237. The second-generation sulfonylureas: change or progress?
  238. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?
  239. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas
  240. Clinical pharmacology of sulfonylureas
  241. Pharmacoepidemiologic and in vitro evaluation of potential drug–drug interactions of sulfonylureas with fibrates and statins
  242. The structure–activity relationship in herbicidal monosubstituted sulfonylureas
  243. Efficient Synthesis, Characterization, and Antibacterial Activity of Novel N-Acylsulfonamides and Sulfonylureas
  244. Trial for transdermal administration of sulfonylureas
  245. A facile synthesis of sulfonylureas via water assisted preparation of carbamates
  246. Dose‐response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes
  247. Adsorption of sulfonylureas onto activated charcoal in vitro
  248. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis
  249. Failure of sulfonylureas to suppress plasma glucagon in man
  250. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas
  251. The Stimulus‐Secretion Coupling of Glucose‐Induced Insulin Release VIII. Combined Effects of Glucose and Sulfonylureas
  252. Glucose and sulfonylureas modify different phases of the membrane potential change during hypoxia in rat hippocampal slices
  253. Combination therapy with insulin and sulfonylureas for type II diabetes
  254. Determination of sulfonylureas in cereal samples with electrophoretic method using ionic liquid with dispersed carbon nanotubes as electrophoretic buffer
  255. Early transition from insulin to sulfonylureas in neonatal diabetes and follow‐up: Experience from China
  256. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure
  257. Cardiovascular effects of pioglitazone or sulfonylureas according to pretreatment risk: moving toward personalized care
  258. … of a potassium conductance in rat midbrain dopamine neurons by intracellular adenosine triphosphate (ATP) and the sulfonylureas tolbutamide and glibenclamide
  259. Warm-up’phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas
  260. Sulfonylureas: Effects in vivo and in vitro
  261. WITHDRAWN: A comprehensive structure–activity analysis of 5-Carboxyl Imidazolyl biphenyl Sulfonylureas derivatives angiotensin AT1 receptor antagonists: 2D-and …
  262. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/-Model
  263. Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group
  264. Comparative effect of initiating metformin versus sulfonylureas on breast cancer risk in older women
  265. The stimulus-secretion coupling of glucose-induced insulin release—XVII: effects of sulfonylureas and diazoxide on insular biosynthetic activity
  266. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year
  267. Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
  268. Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas
  269. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum
  270. Sulfonylureas and platelet function
  271. The pancreatic β-cell recognition of insulin secretagogues: IV. islet uptake of sulfonylureas
  272. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy Gliclazide vs. other sulfonylureas
  273. Hormone-regulated K+ channels in follicle-enclosed oocytes are activated by vasorelaxing K+ channel openers and blocked by antidiabetic sulfonylureas.
  274. Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+ ATP opener nicorandil in experimental …
  275. Sulfonylureas: new high potency herbicides
  276. Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells
  277. Cost‐Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand
  278. Targeting of the Virulence Factor Acetohydroxyacid Synthase by Sulfonylureas Results in Inhibition of Intramacrophagic Multiplication of Brucella suis
  279. Persistence of sulfonylureas in Pullman clay loam
  280. Effects of feeding and fasting on the insulin secretory response to glucose and sulfonylureas in intact rats and isolated perfused rat pancreas
  281. Long-acting sulfonylureas–long-acting hypoglycaemia
  282. Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 rat skeletal muscle cells.
  283. Frequencyof Severe Hypoglycemia in Patients with Non-Insulin Dependent Diabetes Mellitus Treated with Sulfonylureas or Insulin
  284. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II-“The cons”
  285. Sulfonylureas in the treatment of diabetes mellitus—1985
  286. Selective synthesis of sulfonylureas and carboxysulfamides a novel route to oxazolidinones.
  287. The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual …
  288. Hepatic effect of sulfonylureas
  289. Are sulfonylureas passé?
  290. Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets
  291. Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H] glyburide binding to rat brain synaptosomes
  292. Comparative single‐dose kinetics and effects of four sulfonylureas in healthy volunteers
  293. Direct measurements of increased free cytoplasmic Ca2+ in mouse pancreatic β-cells following stimulation by hypoglycemie sulfonylureas
  294. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control
  295. Mexican Carriers of the HNF1A p.E508K Variant Do Not Experience an Enhanced Response to Sulfonylureas
  296. The mass spectrometry of sulfonylureas. I. Mechanisms for the loss of sulfur dioxide
  297. Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo
  298. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 …
  299. Liquid chromatography mass/spectrometry multiresidue determination of sulfonylureas after on‐line trace enrichment
  300. Oral hypoglycemic agents: Sulfonylureas and meglitinides
  301. Effects of the sulfonylureas on muscle glucose homeostasis
  302. Sulfonylureas inhibit metabolic flux through rat liver pyruvate carboxylase reaction.
  303. Ineffectiveness of sulfonylureas in alloxan diabetic rats.
  304. Hypoglycemic action of sulfonylureas in patients with diabetes mellitus
  305. Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics
  306. Extractable insulin of the pancreas and effectiveness of oral hypoglycaemic sulfonylureas in the treatment of diabetes in man; a comparison.
  307. Mortality and cardiovascular risk of sulfonylureas in South Asian, Chinese and other Canadians with diabetes
  308. Sulfonylureas activate glucose transport and protein kinase C in rat adipocytes
  309. Prostanoid-induced contractions are blocked by sulfonylureas
  310. Metabolism of antidiabetic sulfonylureas in man: I. Biological half-lives of the p-acetylbenzenesulfonylureas, U-18536 and acetohexamide and their metabolites
  311. Evaluation of the in vivo efficacy of novel monosubstituted sulfonylureas against H37Rv and extensively drug-resistant tuberculosis
  312. Sulfonylureas and mortality in diabetic patients after myocardial infarction
  313. Differential sensitivity of plant and yeast MRP (ABCC)-mediated organic anion transport processes towards sulfonylureas
  314. Studies of the mode of action of the sulfonylureas and phenylacetamides in enhancing the effect of vasopressin
  315. A screening test for detecting sulfonylureas in plasma
  316. Interactions of sulfonylureas with plasma proteins
  317. Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: results from the DIMORA study
  318. Sulfonylureas stimulate glucose uptake through GLUT4 transporter translocation in rat skeletal muscle
  319. Three-dimensional quantitative structure− activity relationship analysis of the new potent sulfonylureas using comparative molecular similarity indices analysis
  320. Sulfonylureas and the heart
  321. Ion channel effects of antidiabetic sulfonylureas
  322. Effects of sulfonylureas, α-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes
  323. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
  324. Synthesis of heterocyclic sulfonylureas
  325. Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: results from OBSTACLE …
  326. … ) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia …
  327. A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARγ-binding patterns
  328. Disturbances in autoregulatory responses of rat pial arteries by sulfonylureas
  329. Ionophoretic activity of hypoglycemic sulfonylureas.
  330. Screening and simultaneous quantitative measurement of six sulfonylureas in serum by liquid chromatography/mass spectrometry with atmospheric-pressure …
  331. Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA. IT trial.
  332. Quantitative liquid chromatography of sulfonylureas in pharmaceutical products
  333. Operative Condition–Dependent Response of Cardiac ATP-Sensitive K+ Channels Toward Sulfonylureas
  335. … with highly charged polyelectrolytes and carbon nanotubes co-aggregated with sodium dodecyl sulphate for the analysis of sulfonylureas by capillary electrophoresis
  336. Regulation of cloned ATP-sensitive K channels by adenine nucleotides and sulfonylureas: interactions between SUR1 and positively charged domains on Kir6. 2
  337. Assay of sulfonylureas in human plasma by high-performance liquid chromatography
  338. Interacting effects of sulfonylureas and glucose on cyclic AMP metabolism and insulin release in pancreatic islets of the rat
  339. Biosynthesis of proinsulin and insulin in newborn rat pancreas. Interaction of glucose, cyclic AMP, somatostatin, and sulfonylureas on the (3H) leucine incorporation …
  340. Novel benzothiazole based sulfonylureas/sulfonylthioureas: design, synthesis and evaluation of their antidiabetic potential
  341. Synthesis and resolution of sulfonimidamide analogs of sulfonylureas
  342. A convenient synthesis of sulfonylureas from carboxylic acids and sulfonamides via an in situ Curtius rearrangement
  343. Binding study of sulfonylureas and phenothiazines to bovine serum albumin using difference spectrophotometry
  344. Long-term experience with sulfonylureas and placebo
  345. Acid and glucose-6-phosphatase activity of pancreatic B cells after cortisone and sulfonylureas.
  346. Potentiation of hypoglycemic effect of sulfonylureas by halofenate
  347. Balanced AT1 and AT2 angiotensin II antagonists. I. New orally active 5-carboxyl imidazolyl biphenyl sulfonylureas
  348. Effect of sulfonylureas on triglyceride metabolism in the rat liver: possible role of the lysosomes in hepatic lipolysis.
  349. Sulfonylureas and hypoglycemia
  350. Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non‐obese patients with type 2 diabetes
  351. Synthesis, characterization and in vitro antimicrobial activity of novel sulfonylureas of 15-membered azalides
  352. Dual actions of sulfonylureas and glyburide: Receptor and post-receptor effects
  353. Diabetes care for patients experiencing homelessness: beyond metformin and sulfonylureas
  354. Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cells
  355. … between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and …
  356. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas
  357. Effects of sulfonylureas on the synthesis and secretion of plasminogen activator from bovine aortic endothelial cells.
  358. Assessment of the effects of sulfonylureas herbicide amidosulfuron application on target and non-target organisms.
  359. Influence of sulfonylureas on the secretion, disposal and effect of insulin
  360. Drug-induced desensitization of insulinotropic actions of sulfonylureas
  361. A mutation confers Monochoria vaginalis resistance to sulfonylureas that target acetolactate synthase
  362. Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation
  363. Sulfonylureas and meglitinides: historical and contemporary issues.
  364. Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts
  365. Fasiglifam/TAK-875, a selective GPR40 agonist, improves hyperglycemia in rats unresponsive to sulfonylureas and acts additively with sulfonylureas
  366. Sulfonylureas as Dual Acting Agents—Synthesis and Biological Activity
  367. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes
  368. Effect of sulfonylureas administered centrally on the blood glucose level in immobilization stress model
  369. Long-Term Actions of Sulfonylureas on (Pro-) Insulin Biosynthesis and Secretion-I. Lack of Evidence for a Compensatory Increase in (Pro-) Insulin Biosynthesis After …
  370. Extrapancreatic effects of sulfonylureas: Potentiation of insulin action through post-binding mechanisms
  371. Counterpoint: a diabetes outcome progression trial (ADOPT): good for sulfonylureas?
  372. Measurement of antidiabetic sulfonylureas in serum by gas chromatography with electron-capture detection
  373. Design, synthesis and herbicidal activity of novel sulfonylureas containing triazole and oxadiazole moieties
  374. Reactions with 1-benzotriazolecarboxylic acid chloride. V Synthesis of sulfonylureas and related compounds
  375. Effects of sulfonylureas on membrane-bound low Km cyclic AMP phosphodiesterase in rat fat cells
  376. Different sulfonylureas induce the apoptosis of proximal tubular epithelial cell differently via closing KATP channel
  377. Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment
  378. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages
  379. Research on the structure/activity relationship of herbicidal sulfonylureas
  380. Inhibitory effect of sulfonylureas on protein phosphatase activity in rat pancreatic islets
  381. On the possible role of thiol groups in the insulin-releasing action of mercurials, organic disulfides, alkylating agents, and sulfonylureas
  382. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas
  383. Mode of action of sulfonylureas
  384. Determination of sulfonylureas and metabolites by pyrolysis gas chromatography
  385. Chiral recognition of pinacidil and its 3-pyridyl isomer by canine cardiac and smooth muscle: antagonism by sulfonylureas.
  386. Sulfonylureas: New high potency herbicides
  387. Low-dose rosiglitazone (RSG) provides additional glycemic control when combined with sulfonylureas in type 2 diabetes (T2D)
  388. Effect of sulfonylureas on hepatic glycogen metabolism: Activation of glycogen phosphorylase
  389. Heterogeneity of the inhibitory influence of sulfonylureas on prostanoid-induced smooth muscle contraction
  390. Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients
  391. Third‐line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin
  392. Synergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats
  393. Factors associated with physicians’ decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients
  394. Effects of sulfonylureas on KATP channel-dependent vasodilation
  395. Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study
  396. Abuse of sulfonylureas: Is factitious hypoglycemia a cause for concern?
  397. Metabolic effects of hypoglycemic sulfonylureas—II: In vitro effect of sulfonylureas on cell-free protein synthesis and energy metabolism in rat tissues
  398. Design, Synthesis and in Vivo Evaluation of Novel Glycosylated Sulfonylureas as Antihyperglycemic Agents
  399. Synthesis and herbicidal activity of novel sulfonylureas containing thiadiazol moiety
  401. Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas
  402. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without …
  403. Inhibition of catecholamine release by tolbutamide and other sulfonylureas
  404. Effects of sulfonylureas on histochemical and ultracytochemical calcium distribution in B-cells of mice
  405. Exploring the distribution of prescription for sulfonylureas in patients with type 2 diabetes according to cardiovascular risk factors within a Canadian primary …
  406. Interaction of the Cytosolic Domains of the Kir6.2 Subunit of the KATP Channel Is Modulated by Sulfonylureas
  407. Sulfonylureas: Assets in the past, present and future
  408. Effect of sulfonylureas on hepatic fatty acid oxidation
  409. Effects of sulfonylureas on the pancreas
  410. The Reaction of Sulfonylureas and Sulfonamides with Carbonyl Chloride. A New Synthesis of Isocyanates1
  411. Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor
  412. The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics.
  413. Homologous and hybrid calcium complexes of A23187 and hypoglycemic sulfonylureas: nuclear magnetic resonance and conformational analysis
  414. Analysis of the sulfonylurea herbicide metsulfuron-methyl and its metabolites in the soil of cereal crops. Comparative analytical chemistry of the sulfonylureas
  415. Antihypertensive drug therapy and hypoglycemia in elderly diabetic patients treated with insulin and/or sulfonylureas
  416. Processing and transport of insulin by vascular endothelial cells: effects of sulfonylureas on insulin receptors
  417. Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors
  418. Original Articles; Inhibition of Acetohydroxyacid Synthase by Sulfonylureas and Imidazolinones
  419. Augmentation of the effects of insulin and insulin-like growth factors I and II on glucose uptake in cultured rat skeletal muscle cells by sulfonylureas
  420. Therapeutic aspects of sulfonylureas: a brief review
  421. Thermal Dissociation of Sulfonylureas II: Dissociation of Four N-and N′-Substituted Sulfonylureas in Different Media
  422. Hypoglycemic Sulfonylureas Antagonize the Effects of Cromakalim and Pinacidil on 86Rb Fluxes and Contractile Activity in the Rat Aorta
  423. Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus
  424. Extrapancreatic action of sulfonylureas: hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase
  425. Conjugates of degraded and oxidized hydroxyethyl starch and sulfonylureas: Synthesis, characterization, and in vivo antidiabetic activity
  426. Inositol hexakisphosphate and sulfonylureas regulate β-cell protein phosphatases
  427. Effects of sulfonylureas on adipocyte and skeletal muscle insulin action in patients with non-insulin-dependent diabetes mellitus
  428. Dose-response relationships of sulfonylureas: will doubling the dose double the response?
  429. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in …
  430. Pharmacogenomics of Sulfonylureas response in relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 regulatory subunit-associated protein 1 …
  431. Within-class differences of the sulfonylureas should be accounted for
  432. Clinical pharmacology of sulfonylureas
  433. Synthesis and biological evaluation of sulfonylcyanoguanidines and sulfonamidonitroethylenes as bioisosteres of hypoglycemic sulfonylureas
  434. Uncoupling action of sulfonylureas on brown fat cells
  435. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
  436. Design, syntheses and biological activity of novel ALS inhibitors (IX) CoMFA of sulfonylureas and triazolopyrimidine-2-sulfonamides ALS inhibitors
  437. Pyrolysis—gas chromatography/mass spectrometry and electron impact-, fast atom bombardment-mass spectrometry of sulfonylureas
  438. Comparison of the effects of three sulfonylureas on in vivo insulin action
  439. Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas
  440. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
  441. Relaxant effects of sulfonylureas on induced contractions of rat uterine smooth muscle: role of intracellular calcium.
  442. Pancreatic action of the sulfonylureas
  443. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats.
  444. Extrapancreatic effects of hypoglycemic sulfonylureas: still a controversial issue
  445. Antidiabetic sulfonylureas relax isolated rabbit coronary arteries
  446. Metabolic effects of hypoglycemic sulfonylureas—I: In vitro effect of sulfonylureas on leucine incorporation and metabolism and on respiration of rat tissues
  447. Teratogenic effects of sulfonylureas and insulin in rats
  448. Sulfonylureas and related compounds
  449. Oral sulfonylureas for the treatment of type II diabetes: an update.
  450. Modern Sulfonylureas Strike Back–Exploring the Freedom of Flexibility
  451. Effects of biguanides and sulfonylureas on insulin receptors in cultured cells.
  452. The Positive Inotropic Action of Sulfonylureas: A Mechanism Independent of Cyclic Adenosine 3′, 5′-Monophosphate
  453. Long-Term Actions of Sulfonylureas on (Pro-) Insulin Biosynthesis and Secretion-II. Studies after Administration of Tolbutamide and Glibenclamide to Rats In Vivo
  454. A kinetic study of the methanolysis of the sulfonylureas bensulfuron methyl and sulfometuron methyl using capillary electrophoresis
  455. Syntheses and tissue distribution of 99mTc-sulfonylureas
  456. Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
  457. Metabolic effects of hypoglycemic sulfonylureas—V: In vitro effects of sulfonylureas on mitochondrial adenosine triphosphatase activity
  458. Lack of Ca2+ ionophoretic activity of hypoglycemic sulfonylureas in excitable cells and isolated secretory granules
  459. Lipids behavior and adverse effects for oral antidiabetic agents in patients with type2 diabetes treated with sulfonylureas alone based on systematic review
  460. Permeation of Sulfonylureas through Cellulose and Dimethylpolysiloxane Membranes
  461. A strategy of chemical control of Apera spica-venti L. resistant to sulfonylureas traced on the molecular level
  462. Regulation of muscle fructose 2, 6-bisphosphate levels by sulfonylureas
  463. Design, syntheses and biological activities of novel sulfonylureas containing an oxime ether moiety
  464. Effects of sulfonylureas on the actions of insulin and insulin-mimickers: potentiation of stimulated hexose transport in adipocytes
  465. Ischemia in type 2 diabetes: tissue selectivity of sulfonylureas and clinical implications
  466. Do hypoglycemic sulfonylureas inhibit Na+, K+-ATPase activity in pancreatic islets?
  467. Analysis of secondary failure to sulfonylureas in type 2 diabetics. A retrospective study for 1976–1987
  468. Glucagon and growth hormone secretion in insulin-treated diabetics: effects of added sulfonylureas
  469. Combination of insulin and sulfonylureas: a literature review
  470. Transport of Pr3+ by hypoglycemic sulfonylureas across liposomal membranes
  471. Sulfonylureas and meglitinides: insights into physiology and translational clinical utility
  472. Displacement of sulfonylureas from human serum proteins by coumarin derivatives and cortical steroids
  473. Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors
  474. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus
  475. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany
  476. Capillary electrophoretic behavior of seven sulfonylureas.
  477. A Radioimmunoassay for Determination of Glibenclamide and Other Sulfonylureas
  478. Silent hypoglycaemic episodes among well controlled type 2 diabetic patients treated with sulfonylureas
  479. Metabolic effects of hypoglycemic sulfonylureas—IV: Interference of sulfonylureas with mitochondrial oxidative phosphorylation
  480. Pharmacodynamic herb-drug interactions: the effects of Azadirachta indica leaf extracts on two commonly used second generation sulfonylureas
  481. Effects of chronic and acute treatment with sulfonylureas on plama insulin and glucose levels in the rat.
  482. Prediction of therapeutic doses of sulfonylureas based on receptor occupancy theory
  483. Synthesis and herbicidal activity of sulfonylureas; SL-950 and its related compounds
  484. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide
  485. Preparation of Some Additional Sulfonylureas.
  486. Effect of sulfonylureas on the permeability to water and electrical properties of the urinary bladder of the toad
  487. Thermal dissociation of sulfonylureas: Dissociation of tolbutamide in a series of aliphatic alcohols and in polyethylene glycol 400
  488. Observations of the mechanism of action of the sulfonylureas under clinical conditions
  489. Sulfonylureas mimic glucose in stimulating the uptake of Na+ in pancreatic islets exposed to ouabain
  490. Metabolic effects of sulfonylureas in normal men and in various types of diabetic patients
  491. … A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia …
  492. Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of …
  493. Synthesis and herbicidal activity of sulfonylureas with fused heterocyclic moiety
  494. Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureas
  495. Sulfonylureas as treatment choice in Diabetes Mellitus: Where are we now?
  496. Interaction of sulfonylureas with the transport of bile acids into hepatocytes
  497. Metabolic effects of hypoglycemic sulfonylureas—III: Effect of chlorpropam1de on energy metabolism and ketogenesis in the isolated perfused rat liver
  498. Effect of hypoglycemic sulfonylureas on hepatic fructose metabolism in the rat
  499. Evidence for more than one binding site for sulfonylureas in insulin‐secreting cells
  500. Evaluation of first-generation sulfonylureas and glipizide in non-insulin-dependent diabetes mellitus
  501. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas
  502. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke
  503. Do sulfonylureas still have a role in type 2 diabetes?
  504. Role of Sulfonylureas in Non-Insulin-Dependent Diabetes Mellitus: Part I-“The pros”
  505. Does mortality risk vary among sulfonylureas?
  506. Sulfonylureas as second line treatment for type 2 diabetes
  507. O-Dealkylation of coumarin ethers and effects of inducers, inhibitors, and sulfonylureas on rice cytochrome P-450
  508. Comparative Effects of Three Sulfonylureas (Glibenclamide, Glimepiride, and Gliclazide) on Proliferation and Migration of Vascular Smooth Muscle Cells.
  509. Respiration of the β-cells in the presence of sulfonylureas
  510. Clinical pharmacokinetics of sulfonylureas: a brief review.
  511. New fluoro intermediates for herbicidal sulfonylureas
  512. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients.
  513. Synthesis and Herbicidal Activities of Sulfonylureas Bearing 1, 3, 4‐Thiadiazole Moiety
  514. Chemical control of branched broomrape in processing tomato using sulfonylureas in Southern Italy
  515. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: results of a two-phase study
  516. Persistence of sulfonylureas on alkaline soils in south-eastern Australia and the potential damage to subsequent crops and pastures
  517. Transcription factor 7-like 2 rs7903146 polymorphism and therapeutic response to sulfonylureas in patients with type 2 diabetes
  518. On the stability of zwitterions of pyridine sulfonylureas: the effect of isosterism, acidity, and microsolvation
  519. Sulfonylureas activate glycogen phosphorylase and increase cytosolic free-Ca2+ levels in isolated rat hepatocytes
  520. The clinical effects of levosimendan are not attenuated by sulfonylureas
  521. A 12-h Intravenous Insulin Infusion Restores the [beta]-Cell Response Torpidity to Sulfonylureas in Patients Affected by Type 2 Diabetes
  522. Microvascular permeability with sulfonylureas in normal and diabetic hamsters
  523. Synthesis and herbicidal activities of pyridyl sulfonylureas: More convenient preparation process of phenyl pyrimidylcarbamates
  524. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas
  525. Study on the bioactivity changes of hydroxylated sulfonylureas derivatives: A possible metabolism
  526. Effects of sulfonylureas (tolbutamide, glipentide and glibenclamide) on in vitro glycerol metabolism in adipose tissue from rats
  527. Stoichiometry of calcium binding by hypoglycemic sulfonylureas.
  528. Design, synthesis and bioactivity of novel ALS inhibitors (V) Initial model of the herbicidal sulfonylureas and fused heterocyclic sulfonamides binding with receptor
  529. Comparing the effect of dipeptidyl-peptidase 4 inhibitors and sulfonylureas on albuminuria in patients with newly diagnosed type 2 diabetes mellitus: A prospective …
  530. Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas
  531. … or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
  532. Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas. Follow up at two years.
  533. Effectiveness of Nateglinide on In Vitro Insulin Secretion from Rat Pancreatic Islets Desensitized to Sulfonylureas
  534. International diabetes federation meeting, 1997: Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone
  535. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: a real world analysis of the South …
  536. Hyaluronidase-induced inhibition of the insulinotropic action of sulfonylureas, leucine, and glucagon in rodent isolated pancreatic islets
  537. Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas
  538. Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabetes mellitus
  539. Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia
  540. Factors moderating the effect of oral sulfonylureas on free water clearance
  541. The synthesis of some new sulfonylureas
  542. Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients
  543. Sulfonylureas and ischemic heart disease
  544. Theoretical study on conformation-related activity of hypoglycemic sulfonylureas
  545. Modulation of glucose metabolism by sulfonylureas in primary cultures of adult rat hepatocytes.
  546. Balanced AT1 and AT2 angiotensin II antagonists. III. potent and orally active 5-β-ketosulfoxide imidazolyl biphenyl sulfonylureas
  547. Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas
  548. Synergistic effect of hypoglycemic sulfonylureas and negative phospholipids on calcium transport: ionic and conformational aspects.
  549. Simple and effective preparation of amino sulfonylureas from amino acids: application to the synthesis of amino sulfonylurea-containing peptidomimetics
  550. Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
  551. Effects of sulfonylureas on patients with type 2 diabetes and acute nonlacunar ischemic stroke
  552. … cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA (1c)>= 8%) on monotherapy with metformin or sulfonylureas
  553. Thiazolidinedione use is associated with improved all-cause mortality compared with sulfonylureas among diabetic hemodialysis patients
  554. Sulfonylureas, Science and Serendipity
  555. Continue with long term sulfonylureas in patients with mutations in the KCNJ11 gene when there is evidence of response even if insulin treatment is still required
  556. Hypertension in type 2 diabetes mellitus: do we need to redefine the role of sulfonylureas?
  557. Synthesis and herbicidal activity of 1, 4‐benzoxazin‐3‐one sulfonylureas
  558. Vinylogous sulfonylureas: a new class of acetohydroxyacid synthase inhibitors incorporating a large bridging moiety
  559. Effects of cations, ionophores and hypoglycemic sulfonylureas on the fluorescence of fluorescein-labelled pancreatic islets.
  560. Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription
  562. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  563. Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus
  564. Sulfonylureas—a novel treatment to reduce tissue damage after acute spinal cord injury?
  565. Sulfonylureas: physico-chemical properties, analytical methods of determination and bioavailability
  566. Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
  567. Metabolic effects of hypoglycemic sulfonylureas—VI: Effects of chlorpropamide and carbutamide on ketogenesis and on mitochondrial redox state in the isolated …
  568. Current status of aryl sulfonylureas in treatment of diabetes mellitus
  569. Risk and benefit of sulfonylureas–their role in view of new treatment options for type 2 diabetes
  570. Simultaneous high performance liquid chromatography determination of three sulfonylureas in plasma
  571. How important is the synclinal conformation of sulfonylureas to explain the inhibition of AHAS: a theoretical study
  572. Sulfonylureas and heart disease in diabetes management
  573. Comparing the Efficacy of Amicarbazone, a Triazolinone, with Sulfonylureas forWeed Control inMaize (Zea mays)
  574. Exploring clinical care among adults with diabetes mellitus: alignment with recommended statin and sulfonylureas treatment
  575. New Pyrazole Sulfonylureas: Synthesis and Herbicidal Activity
  576. Decreased responsiveness of gluconeogenesis to the modulation by sulfonylureas in hepatocytes isolated from obese (fa/fa) Zucker rats
  577. MIR4532 gene variant rs60432575 influences the expression of KCNJ11 and the sulfonylureas-stimulated insulin secretion
  578. Effect of hypoglycemic sulfonylureas on Ca2+ fluxes across lipid bilayers
  579. Phytotoxicity of amidosulfuron (sulfonylureas herbicide) to aquatic macrophyte Lemna minor L.
  580. Synthesis and herbicidal activity of bicyclic Sulfonylureas
  581. Sulfonylureas stimulate renin secretion from the perfused kidney of the rat
  582. Suppression by 2-ketoisocaproate of the insulinotropic action of hypoglycemic sulfonylureas.
  583. Circadian variations of carbohydrate tolerance in maturity onset diabetics treated with sulfonylureas
  584. Sulfonylureas induced hypoglycemia in diabetics-a
  585. Antidiabetic sulfonylureas antagonize somatostatin inhibition of prolactin secretion in vitro
  586. Molecularly imprinted ‘traps’ for sulfonylureas prepared using polymerisable ion pairs
  587. Impact of Switching from Sulfonylureas to Dipeptidyl Peptidase-4 Inhibitors on Hypoglycemia Burden in the United States—A Predictive Modeling Approach
  588. Tissue distribution and metabolism of drugs VI: Effect of second drugs on pancreatic distribution and insulin‐releasing activity of sulfonylureas in perfused rat pancreas
  589. Sulfonylureas and cardiovascular mortality in diabetes: a class effect?
  590. Cardiovascular Profile of Modern Sulfonylureas: Focus on Glimepiride
  591. Synthesis, crystal structure and herbicidal activity of novel sulfonylureas containing triazolinone moiety
  592. Synthesis and herbicidal activity of conformationally restricted butyrolactone sulfonylureas
  593. … , ADHERENCE AND THEIR ASSOCIATIONS WITH GLYCEMIC GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH SULFONYLUREAS
  594. The effect of sulfonylureas on the respiratory quotient in diabetic and normal animals
  595. … of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like …
  596. Clinical Pharmacology of Sulfonylureas
  597. Sulfonylureas in today’s blood glucose lowering therapy. New data on advantages and potential barriers of an “old” antidiabetic group
  598. Supercritical fluid extraction of sulfonylureas from aqueous matrices
  599. 1H nuclear magnetic resonance and clinical studies of interaction of calcium antagonists and hypoglycemic sulfonylureas
  600. Design, synthesis and herbicidal activity of novel sulfonylureas containing tetrahydrophthalimide substructure
  601. Supratherapeutic doses of sulfonylureas in diabetic patients: How much is too much?
  602. Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications
  603. Review of safety considerations in the elderly using sulfonylureas
  604. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both?
  605. Sulfonylureas and annual medic regeneration on high pH soils
  606. Efficacy and safety of premixed human insulin combined with sulfonylureas in type 2 diabetic patients previously poorly controlled with insulin
  607. Selectivity of sulfonylureas in seed crops of perennial ryegrass (Lolium perenne L.).
  608. Sulfonylureas in type 2 diabetes mellitus: current evidence, conflicts and clinical implications
  609. Warfarin with sulfonylureas and hypoglycemic events: consider dose, length of treatment, and all sulfonylureas
  610. Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
  611. Combination Use of Sulfonylureas and Insulin in the Treatment of Noninsulin‐Dependent Diabetes Mellitus
  612. Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas
  613. Influence of long-term used herbicides on resistance development in Apera spica-venti L. to sulfonylureas.
  614. Ethnic variations in the risk of hypoglycaemia among people with Type 2 diabetes prescribed insulins and/or sulfonylureas: a historical cohort study using general …
  615. Sulfonylureas in the therapy of type 2 diabetes mellitus: where do we stand today?
  616. Not all sulfonylureas persist for the same time
  617. Stimulation of biliary glutathione secretion by sulfonylureas.
  618. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas
  619. Oral sulfonylureas and CV mortality.
  620. The clinical use of oral sulfonylureas in the management of non-insulin dependent diabetes mellitus (NIDDM).
  621. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on …
  622. Comparison in Rabbits of Hypoglycemia and B Cell Degranulation After Various Sulfonylureas.
  623. A new mesangial triumvirate: Sulfonylureas, their receptors and endosulfines
  624. Evolution of Sulfonylureas: Commentary on Developmental Process and Initial Trials
  625. Binding of sulfonylureas to serum albumin: A response
  626. Conformational analysis of Sulfonylureas
  627. Improving management of type 2 diabetes mellitus: 3. Sulfonylureas
  628. Synthesis of flavone‐3‐sulfonylureas
  629. Synthesis and herbicidal activity of novel sulfonylureas containing 1, 2, 4-triazolinone moiety
  630. The effects of long-term administration of sulfonylureas on the carbohydrate metabolism in normal and alloxanized rats; have sulfonylureas a diabetogenic action?
  631. Discovery of Potent Antihypertensive Ligands Substituted Imidazolyl Biphenyl Sulfonylureas Analogs as Angiotensin II AT1 Receptor Antagonists by Molecular …
  632. Effect of herbicide combinations on biotypes of wind bentgrass (Apera spica-venti) sensitive and resistant to sulfonylureas [Conference poster].
  633. Protein Binding of Sulfonylureas. I. Interaction of Some Substituted Benzenesulfonyl Propylureas to Bovine Serum Albumin
  634. Failure of sulfonylureas in type 2 diabetes
  635. PROGRESS REPORT OF AMERICAN DIABETES ASSOCIATION ON ORALLY EFFECTIVE HYPOGLYCEMIC SULFONYLUREAS: GUEST EDITORIAL
  636. Sulfonylureas Amplify Cyclic 3′, 5′ AMP Mediated Hormone Action
  637. Rational use of sulfonylureas
  638. Antibacterial Activity of Novel Sulfonylureas, Ureas and Thioureas of 15-Membered Azalides
  639. Sulfonylureas Having Diuretic Activity
  640. Quantitative effects of glucose, sulfonylureas, salicylate, and indole-3-acetic acid on the secretion of insulin activity into pancreatic venous blood.
  641. Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas.
  642. Sulfonylureas in the treatment of type II diabetes
  643. Effects of D-glucose during preincubation of pancreatic islets with 45Ca upon the subsequent stimulation of 45Ca outflow by hypoglycemic sulfonylureas and K+.
  644. Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a …
  646. Sulfonylureas and daily blood glucose profiles in elderly diabetics
  647. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed
  648. Comparison of Insulin, Sulfonylurea and Sulfonylureas-Metformin Combination on HbA1c and eGFR Level on Age-, Sex-and BMI-Matched Groups of …
  649. Does insulin+ sulfonylureas= effective treatment of NIDDM?
  650. Study on the vascular effects of chronic administration of two sulfonylureas, chlorpropamide and glibenclamide, on the healthy rat thoracic aorta
  651. The Risk of Mortality Varies Amongst Sulfonylureas: A Meta-analysis of Controlled Studies
  652. A quantum chemical study with special reference to the sulfamyl group of sulfonylureas
  653. Long-Term Actions of Sulfonylureas on (Pro-) Insulin Biosynthesis and Secretion
  654. Response to Comment on Genuth. Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s …
  655. The place of sulfonylureas in the modern treatment of type 2 diabetes mellitus: The end of an era or the beginning of a new one?
  656. Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes
  657. Sulfonylureas at the glomerular battlefield
  659. Metformin and Sulfonylureas Effect on the Blood Level of Prostate Specific Antigen
  660. Precision medicine with sulfonylureas: from clinical studies to bedside practice
  661. CONSUMPTION ANALYSIS OF METFORMIN, SULFONYLUREAS, AND OTHER ANTIDIABETICS DRUGS IN MOROCCO (1991-2005)
  662. Possible Interaction Of Pantoprazole On Sulfonylureas In Diabetic Rats
  663. A study on the safety and injury of sulfonylureas herbicides to cereal crops
  664. SULFONYLUREAS AND THE HEART¹
  665. DPP-4 inhibitors show benefits over sulfonylureas as add-on diabetes therapy
  666. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
  667. … ) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia …
  668. Sensitivity of kochia (Kochia scoparia [L.] Schrader) from three localities to selected sulfonylureas, imazapyr and atrazine.
  669. Severe hypoglycemia caused by Sulfonylureas and Biguanides in a patient with obstructive anuria: Resolution with ureteral stent
  670. Reaction of sulfonylureas with methanol
  671. Risk of heart failure in diabetic patients receiving sulfonylureas
  672. Hypoglycemic adverse reactions to insulin and sulfonylureas.
  673. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (Type II DM)
  674. Metabolites of hypoglycemic sulfonylureas in kidney failure. Experience with glibenclamide
  675. Intensification of Metformin treatment in diabetic patients with Insulin versus Sulfonylureas
  676. Kinetics-effect relations of glipizide and other sulfonylureas.
  677. Insulin vs Sulfonylureas for Second-Line Diabetes Treatment
  678. Glycogen phosphorylase activities in sulfonylureas treated rats
  679. The effect of hypoglycemic sulfonylureas on human red blood cell transglutaminase activity
  680. Pharmacogenetics of sulfonylureas
  681. Economic burden of type 2 diabetes mellitus treatment strategies: A cost consequence analysis of sitagliptin vs sulfonylureas in Lombardy region
  682. Effects of epinephrine and glucose on the in vitro response of adipose tissue to sulfonylureas
  683. Effects of different sulfonylureas on the warm-up phenomenon in diabetes patients with coronary artery disease
  684. Insulin responses to sulfonylureas
  685. Synthesis and herbicidal activity of novel 4-substituted pyrimidinyl-phenyl-sulfonylureas
  686. … of an Oral Antidiabetic Agent Experimental Studies: Extractable Insulin of the Pancreas and Effectiveness of Oral Hypoglycæmic Sulfonylureas in the Treatment of …
  687. Sulfonylureas: Asset or liability?
  688. Time to be cautious about prescribing sulfonylureas?
  689. Sulfonylureas and Related Compounds
  690. Can sulfonylureas induce cardiotoxicity?
  691. The second generation sulfonylureas: glipizide and glyburide
  692. Synthesis of sulfonylureas containing 1, 15-pentadecanolide ring
  693. Pre-Meal and Post-Meal Use of Humalog [R] Mix25 [TM] in Elderly Patients with Type 2 Diabetes and Oral Treatment Inadequacy with Sulfonylureas
  694. Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)
  695. The 32nd Annual Meeting of the European Association for the Study of Diabetes. Leptin, insulin resistance, intrauterine malnutrition, sulfonylureas, oral agents alone …
  696. Protein Binding of Sulfonylureas. II. Interaction of Some p-Toluenesulfonyl-n-alkylureas with Bovine Serum Albumin
  697. A clinical study of the sulfonylureas in diabetes.
  698. Synthesis of novel herbicidal sulfonylureas
  699. In patients with type 2 diabetes who are maximized on metformin with HbA1C above 7%, are GLP-1 agonists more effective than sulfonylureas for lowering HbA1C?
  700. HOMA as a Predictor of Insulin Requirement in Type 2 Diabetes with Apparent Secondary Sulfonylureas Failure
  701. WITHDRAWN: Structural insights for 5-β-Ketosulfoxide Imidazolyl Biphenyl Sulfonylureas derivatives as angiotensin II AT1 receptor antagonists using kNN-MFA with …
  702. Effect of chronic hyperglycemia on islet# beta# cells function in type 2 diabetes mellitus with secondary sulfonylureas failure
  703. Short-term intensive insulin treatment and sensitivity of sulfonylureas
  704. Patients with Type 2 Diabetes on Sulfonylureas Exhibit Significantly Less Neurological Impairment on Admission with First Ever Acute Stroke.
  705. The use of DPP-4 inhibitors versus sulfonylureas as second line therapy in combination with metformin for treatment of Diabetes Mellitus type II
  706. Statistical Analysis of Sulfonamide Allergy Item Annotation in Drug Instructions of Commonly-used Sulfonylureas at Home and Abroad
  707. … , Ogston SA, Emslie-Smith A, Morris AD: Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas …
  708. Risk of CV disorders with insulin or sulfonylureas
  709. Variation in TCF7L2 Influences Glycemic Response to Sulfonylureas.
  710. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
  711. Glucagon-Like Peptide-1S compared to Sulfonylureas in the Treatment of Adults Diagnosed with Type II Diabetes Mellintus in Primary Care
  712. Reply to the letter by P. Guillausseau Regarding “Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet …
  713. … DISEASE-RELATED HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE BID, SULFONYLUREAS, OR INSULIN: A …
  714. COMPARATIVE SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND SULFONYLUREAS IN OLDER ADULTS ACROSS LEVELS OF FRAILTY
  715. Preadmission treatment with sulfonylureas and infarct size after ST-elevation myocardial infarction
  716. Sulfonylureas dosage: from therapeutic monitoring to differential diagnosis of hyperinsulinism
  717. … of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas
  718. Sulfonylureas show unfavourable risk profiles
  719. Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD
  720. Conformational Analysis of Sulfonylureas: Acetohexamide and Tolazamide
  721. The Safety Profile Comparison Between Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas in Diabetic Patients: A Systematic Review and Meta-Analysis
  722. Sulfonylureas associated with hypoglycaemia
  723. A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins and Sulfonylureas as Monotherapy in Patients with Type 2 …
  724. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics
  725. The Use of Sulfonylureas in the Treatment of Adult Onset Diabetes
  726. Who comes in second? The race against sulfonylureas and DPP4s as add-on therapy
  727. CONTROL OF HEPATIC GLUCOSE METABOLISM BY ORAL HYPOGLYCEMIC SULFONYLUREAS.
  728. Balancing Risks in the Choice of Medications for Diabetics with Alcohol Use Disorders: Physicians Prefer Insulin and Sulfonylureas.
  729. 474 Hypoglycemic Agents Sulfonylureas Constrict the Fetal Ductus Arteriosus in the Rat
  730. Influence of sulfonylureas on cardiovascular system: progress in basic research and clinical research
  731. Huizar JF, Gonzalez LA, Alderman J, Smith HS: Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics
  732. Glycemic Effects Linked to Unique Mechanism of Action of Sulfonylureas
  733. Different Therapeutic Regimens for Diabetic Patients with Sulfonylureas Secondary Failure: Cost-Effectiveness Analyses and Evaluation of Life Quality
  734. … or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis”
  735. Blockade of the antinociception induced by diclofenac, but not of indomethacin, by sulfonylureas and biguanides
  736. Comparative Effectiveness between Dipeptidylpeptidase-4 Inhibitors and Sulfonylureas in Combination with Metformin in Type 2 Diabetes Mellitus Patients
  737. Permeation of sulfonylureas through cellulose and dimethylpolysiloxane membranes.
  738. Sulfonylureas increase cancer risk
  739. Cardiovascular safety of DPP-4 inhibitors compared to that of sulfonylureas
  740. Effect of therapy with insulin or sulfonylureas on lipid levels in patients with NIDDM
  741. Circular dichroism studies on the interaction of sulfonylureas with insulin
  742. Concurrent Use of Sulfonylureas and Antimicrobials of the Elderly in Korea: A Potential Risk of Hypoglycemia
  743. Sulfonylureas are associated with a higher adjusted risk of myocardial infarction compared to metformin in patients with type 2 diabetes
  744. Blockade of the antinociception induced by diclofenac, but not of indomethacin, by sulfonylureas and biguanides
  745. Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
  746. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas
  747. Synthesis of some sulfonylureas of potential herbicidal activity
  748. Warfarin+ sulfonylureas: serious hypoglycaemic events
  749. Some Doubts About the Mantra on the Deleterious Cardiovascular Effects of Sulfonylureas
  750. Effects of sulfonylureas (Tolbutamide, Glipentide and Glibenclanide) on in vitro glycerol metabolism in adipose tissue from rats.
  751. SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
  753. The Effects of Long-term Administration of Sulfonylureas on the Carbohydrate Metabolism in Normal and Alloxanized Rats; Have Sulfonylureas a Diabetogenic Action …
  754. Risk of Cardiovascuar Disease in Type 2 Diabetic Women on Sulfonylureas: A Retrospective Case-Control Study
  755. Effects of glucose and sulfonylureas on Ca (2+) entry and the sodium content of pancreatic islets.
  756. Sulfonylureas and Glinides Exhibit PPARγ Activity: A Combined Virtual Screening and Biological Assay Approach
  757. SULFONYLUREAS AND ON-TREATMENT PLATELET REACTIVITY IN TYPE 2 DIABETES MELLITUS PATIENTS
  758. Glucose controls glucagon secretion with minor changes in alpha cell [Ca2+] c whereas sulfonylureas control glucagon secretion by increasing alpha cell [Ca2+] c …
  759. Protonophoretic activity of hypoglycemic sulfonylureas in black lipid membranes
  760. SULFONYLUREAS AND GLINIDES AS NEW PPARγ AGONISTS: VIRTUAL SCREENING AND BIOLOGICAL ASSAYS
  761. Pharmacovigilance‐pharmacological investigations on sulfonylureas and glinides‐induced atrophy in skeletal muscle (1142.5)
  763. Cost-effectiveness Analysis of Three Sulfonylureas in Treatment of Noninsulin Dependent Diabetes Mellitus
  764. Sulfonylureas and cardiovascular effects: From the laboratory to the bedside, clinical data and implications in man
  765. Simultaneous high performance liquid chromatography determination of three sulfonylureas in plasma
  766. Metformin in Combination With Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in The Treatment of Type 2 Diabetes: Clinical And Economic Impact
  767. Sulfonylureas in specific clinical situations: maturity onset diabetes of the young (MODY)
  768. At low glucose arginine stimulates and sulfonylureas or K+ depolarization inhibit glucagon secretion by perifused mouse islets
  769. … ; Moon, So Young; Han, Seung Jin. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors versus Sulfonylureas: A Real-World …
  770. Fasting insulin levels correlate with the incidence of hypoglycemic events in patients with Type 2 Diabetes treated with sulfonylureas: a retrospective cross-sectional …
  771. The concurrent use of sulfonylureas & nicorandil: risk or benefit
  773. Histological Changes in Normal and Alloxanized Rats with Prolonged Administration of Sulfonylureas
  774. … COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VERSUS METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE-2 …
  775. Cardiovascular safety perceptions of sulfonylureas based on evidence
  776. Building Evidence to Assess a Drug Safety Signal: the Association between Sulfonylureas and Adverse Cardiovascular Events
  777. … : Large-scale Meta-analysis of Diverse Ancestry Genome-wide Association Studies to Identify Pharmacogenomic Interactions of Sulfonylureas and ECG Phenotypes
  778. Dosing schedule of second generation sulfonylureas in the treatment of non-insulin dependent diabetes should be revised (A commentary)
  779. Reborn the controversy related with the use of sulfonylureas
  780. Prevalence of Physiological, Pathological and Behavioral Risk Factors in Patients Treated with Antidiabetic Sulfonylureas
  781. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes
  782. Effect of treatment and change of islet function by adding insulin glargine on patients with second failure of sulfonylureas
  783. Severity & Extent Of Myocardial Infarction In Diabetic Patient Taking Insulin & Sulfonylureas
  784. Therapeutic Review of Metformin and Sulfonylureas Regimen for Protection of Cardiac Autonomic Neuropathy in Type 2 Diabetes Mellitus
  785. Synthesis and Herbicidal Activity of Sulfonylureas with Fused Heterocyclic Moiety
  786. Inhibitory effect of sulfonylureas on protein phosphatase activity in rat pancreatic islets.
  787. Correlation entre la circulation coronarienne et les modifications observees sur l’ECG orthogonal (French text, sulfonylureas)
  788. Study of the LADA prevalence among diabetics with secondary sulfonylureas failure
  789. Cost-Effectiveness of Sulfonylureas versus Metformin as First-Line Therapy in Newly Diagnosed Type 2 Diabetes.
  790. 142-LB: First Non-sulfonylurea Type Inhibitors of SUR1 Showed Superior Efficacy over Sulfonylureas, and Reversed Sulfonylurea Failure
  791. Clinical implication of serum insulin determination. Diagnosis and prognosis in patients with apparent secondary failure of treatment with sulfonylureas (author’s transl)
  792. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U: Sulfonylureas improve outcome in patients with type 2 diabetes and acute …
  793. Investigations on the Antilipolytic Activity of Sulfonylureas in Man with Indications on Limit Dosages Concerning their Insulin-Secreting Properties
  794. Hypoglycemia associated with concurrent use of commonly used sulfonylureas and warfarin, an observational analysis
  795. Syntheses and Tissue Distribution of ggmTc-Sulfonylureas
  796. Do sulfonylureas imply a resistance risk in Scandinavia?
  797. Effect of metformin and pioglitazone on serum albumin binding of selected sulfonylureas
  798. Interest of adjuvants and some contact herbicides in tank mix with grassweeds sulfonylureas.
  799. Study of the impact of water hardness on grass weeds control with sulfonylureas.
  800. N1, N3-diarly sulfonylureas as possible anticancer agents
  801. SULFONYLUREAS; NEW HIGH POTENCY
  802. Islets Desensitized to Sulfonylureas In Vitro Retain Responsiveness to Nateglinide but Not Repaglinide
  803. Study of the impact of ferrous ions (Fe2+) concentration and pH on grass weeds control with sulfonylureas.
  804. Type 2 Diabetes: Cardiovascular Outcomes with Metformin and Incretin Combination Therapy Compared to Metformin and Sulfonylureas
  805. Sodium handling by the pancreatic beta-cell: Effects of glucose, sulfonylureas and neuroreceptor agonists.
  806. If not sulfonylureas, then what?
  807. Real world adherence benefits from combination products utilized in diabetics: Sulfonylureas & metformin
  808. INHIBITION OF FATTY ACID OXIDATION BY SULFONYLUREAS
  809. Physician Reported Reasons for discontinuing or down-Titrating Sulfonylureas In type 2 Diabetes Patients
  810. Effects of epinphrine and glucose on the in vitro response of adipose tissue to sulfonylureas.
  811. Sulfonylureas Are Associated With Elevated Risk Of Hip Fractures Among Elderly Men And Women With Type-2 Diabetes
  812. A MATHEMATICAL ANALYSIS OF THE BINDING OF THREE HYPOGLYCEMIC SULFONYLUREAS TO NORMAL AND ACETYLATED HUMAN SERUM ALBUMIN.
  813. Future perspective on pharmacogenomics of severe hypoglycemia associated with sulfonylureas: reply from the authors
  814. Sulfonylureas in the Management of Type II Diabetes Mellitus
  815. Insulin vs Sulfonylureas for Second-Line Diabetes Treatment
  816. Insulin vs Sulfonylureas for Second-Line Diabetes Treatment—Reply
  817. Insulin vs Sulfonylureas for Second-Line Diabetes Treatment—Reply
  818. Sulfonylureas—a novel treatment to reduce tissue damage after acute spinal cord injury?–Authors’ reply
  819. A Systematic Review on Hypoglycemia Rate Attributable to Sulfonylureas Utilization in Randomized Controlled Trials of SGLT2 Inhibitors
  820. 014 Impact of type of pre-admission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction
  821. Role Of Sulfonylureas In Perihematomal Edema In Spontaneous Intracerebral Hemorrhage (N8. 002)
  822. Changes in plasma amino acids levels and in vivo gluconeogenesis from alanine in rats chronically treated with sulfonylureas.
  823. Distribution of diuretics and hypoglycemic sulfonylureas in rabbit erythrocytes
  824. THE FIRST LINE DRUG IN HYPOGLYCEMIC THERAPY: METFORMIN OR SULFONYLUREAS?
  825. Sulfonylureas in Type 2 Diabetes: A Case Discussion
  826. sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics Journal
  827. Antihypertensives and the Risk of Serious Hypoglycemia in Older Persons Using Insulin or Sulfonylureas
  828. Effects of imidazolinones and sulfonylureas on jimsonweed seed production and seedling emergence
  829. Effects of sulfonylureas on left ventricular mass in type
  830. Regulation of metabolic effects in L6 muscle cells by sulfonylureas and the protein tyrosine phosphatase inhibitors vanadate and pervanadate
  831. THE SYNTHESIS OF POTENTIAL HYPOGLYCEMIC SULFONYLUREAS
  832. Sulfonylureas: Physico-chemical Properties, Analytical Methods of Determination
  834. The effects of glucose, glucagon and sulfonylureas on insulin release from chicken pancreatic pieces
  835. SHOULD SULFONYLUREAS REMAIN THE DRUGS OF FIRST CHOICE IN ADDITION TO METFORMIN?
  836. Risk Factors Associated With Treatment Discontinuation and Down-titration in Type 2 Diabetes Patients Treated With Sulfonylureas
  837. Hypoglycemic Adverse Reactions to Insulin and Sulfonylureas
  838. The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review
  839. Investigating the effect of low-dose sulfonylureas on glucagon secretion in diabetes mellitus
  840. Synthesis and investigation of the physical properties of some related sulfonylureas
  841. Pharmacogenomics of Sulfonylureas and Glinides on ATP-Sensitive Potassium Channel
  842. Performance of DPP-4-inhhibitors versus sulfonylureas on top of metformin in a real world setting-results of 2 years FU of DiaRegis
  843. Sulfonylureas: Scoring beyond START STUDY
  844. Indications and methods of treatment with sulfonylureas in NIDDM patients
  845. Reply to the Letter to the Editor from van der Wal and Heine (Insulin responses to sulfonylureas)
  846. All-things Insulin, Metformin, GLP-1, Sulfonylureas
  847. SULFONYLUREAS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS TODAY. IS THERE A PROSPECT?
  848. Synthesis and first evaluation of new 18F‐labelled sulfonylureas for the determination of the beta‐cell status in vivo
  849. PDB10 Effectiveness of Vildagliptin Compared to Sulfonylureas in Type 2 Diabetes Patients in Germany: Results From a Large Real-Life Cohort Study
  850. Popularity of Sulfonylureas in Real-World Practice: Perspective from Diabetes Forward
  851. Field soil dissipation of sulfonylureas-study design and results.
  852. … . Its revisions include a new chapter on the” finger-stick” method of self-glucose testing, along with reviews of the” second-generation” sulfonylureas and the use …
  853. … using tolbutamide and tolazamide in normal and diabetic subjects. Various aspects of the prolonged use of tolazamide in comparison with other sulfonylureas
  854. Budgetary Impact of Thiazolidinedione (TZD) Add-On Therapy Relative to Insulin (INS) Add-On Therapy in Individuals Treated with Sulfonylureas (SU): A Third Party …
  855. Studies on the metabolism of ketone bodies and pyruvic acid in patients with various endocrine disorders. 3. Effects of sulfonylureas, biguanides and insulin on the …
  856. Supplementary material A facile synthesis of Sulfonylureas via water assisted preparation of Carbamates
  857. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in
  858. Additions and Corrections-Sulfonylureas Having Diuretic Activity
  859. Effects of sulfonylureas and clofibrate on insulin receptors in cultured human lymphocytes
  860. Effects of metformin and sulfonylureas on overall and colorectal cancer-specific mortality.
  861. Sulfonylureas trigger Ca2+-dependent Epac2 recruitment and Rap activation at the plasma membrane in β-cells
  862. Plasma Concentrations Of FAM3D Protein Is Higher In Individuals With Type 2 Diabetes Mellitus Treated With Sulfonylureas
  863. A patient on insulin plus sulfonylureas
  864. Two-Year Assessment of the Therapeutic Efficacy of Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in Japanese Drug-Naive Patients With Type 2 Diabetes (JDDM …
  865. 1 A New Mesangial Triumvirate: Sulfonylureas, Their Receptors and Endosulfines
  866. 1. Supplementary a. Late Complications of Diabetes Mellitus: Risk Factors in Patients on Sulfonylureas for More than 10 Years
  867. PERFORMANCE OF DPP-4 INHHIBITORS VERSUS SULFONYLUREAS ON TOP OF METFORMIN IN A REAL WORLD SETTING: RESULTS OF TWO-YEAR FOLLOW …
  868. SWITCHING FROM INSULIN TO ORAL SULFONYLUREAS IN PATIENTS WITH PERMANENT NEONATAL DIABETES—CASE REPORT.
  869. Sulfonylureas Tied to Mortality in MI Survivors
  870. Sulfonylureas in permanent neonatal diabetes mellitus due to an activating mutation of Kir6. 2
  871. … insulin exocytosis through glucose sensing and drug signaling: With special focus on serine/threonine protein phosphates and hypoglycemic sulfonylureas
  872. Comparative embryotoxicological analysis of metformin (Biguanide) and glibenclamide (Sulfonylureas), using Zebrafish Embryotoxicity Test (ZFET)
  873. A novel approach to support evidence-based medicine: should sulfonylureas remain an acceptable therapy for diabetes?
  874. Sulfonylureas-a new dimension in weed control.
  875. Effectiveness of sulfonylureas against Orobanche sp. on tomato.
  876. Combined use of mineral fertilizers and sulfonylureas.
  877. Herbicides: Sulfonylureas
  878. Correction of pseudoresistance to sulfonylureas with amaryl
  879. Primary Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas: a Case-Control Study (P1. 244)
  880. Design, synthesis and pharmacological evaluation of sulfonylureas and sulfonycyanoguanidines as thromboxane A2 receptor antagonists. Insights into selectivity …
  881. Mechanisms and characteristics of sulfonylureas and glinides
  882. The role of sulfonylureas in the treatment of type 2 diabetes
  883. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs
  884. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
  885. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events …
  886. Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes
  887. The effect of CYP2C9 genotype variants in type 2 diabetes on the pharmacological effectiveness of sulfonylureas, diabetic retinopathy, and nephropathy
  888. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy
  889. Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas
  890. Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study
  891. Comparative safety of sodium–glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis
  892. Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas
  893. Comparative safety of dipeptidyl peptidase‐4 inhibitors and sulfonylureas among frail older adults
  894. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
  895. Comparison of Mitochondrial Adenosine Triphosphate–Sensitive Potassium Channel High-vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients …
  896. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes
  897. Sulfonylureas and the risk of ventricular arrhythmias among people with type 2 diabetes: a systematic review of observational studies
  898. Broad-specific immunochromatography for simultaneous detection of various sulfonylureas in adulterated multi-herbal tea
  899. Effects of sulfonylureas on periodontopathic bacteria-induced inflammation
  900. Concomitant use of sulfonylureas and warfarin and the risk of severe hypoglycemia: population-based cohort study
  901. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of …
  902. Hospitalization for heart failure among patients with diabetes mellitus and reduced kidney function treated with metformin versus sulfonylureas: a retrospective cohort …
  903. A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas
  904. Glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes and risk of severe hypoglycemia and death: an observational study
  905. Second-generation antidiabetic sulfonylureas inhibit Candida albicans and Candidalysin-mediated activation of the NLRP3 inflammasome
  906. Generation of sulfonylureas under photoredox catalysis and their biological evaluations
  907. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study
  908. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus
  909. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes
  910. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse …
  911. Complementary strategy enhancing broad-specificity for multiplexed immunoassay of adulterant sulfonylureas in functional food
  912. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout
  913. Sulfonylureas for treatment of periodontitis-diabetes comorbidity-related complications: killing two birds with one stone
  914. Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: an experience with conceptual replication in two independent populations
  915. Sulfonylureas in the current practice of type 2 diabetes management: are they all the same? Consensus from the Gulf Cooperation Council (GCC) countries …
  916. Transformation of iodosulfuron-methyl into ionic liquids enables elimination of additional surfactants in commercial formulations of sulfonylureas
  917. Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study
  918. Photo-switchable sulfonylureas binding to ATP-sensitive potassium channel reveal the mechanism of light-controlled insulin release
  919. Hypoglycemia risk with SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists versus sulfonylureas among medicare insured adults with CKD in the …
  920. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging
  921. Latest evidence on sulfonylureas: what’s new?
  922. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis
  923. Pretreatment of sulfonylureas reducing perihematomal edema in diabetic patients with basal ganglia hemorrhage: a retrospective case-control study
  924. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
  925. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb …
  926. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: a multicenter cross‐sectional …
  927. The place of sulfonylureas in guidelines: why are there differences?
  928. Computer-assisted improvement of sulfonylureas with antifungal properties and limited herbicidal activity: potential application in forage conservation
  929. Recent advances in the synthesis of sulfonylureas
  930. Design, synthesis and biological evaluation of 5‑substituted sulfonylureas as novel antifungal agents targeting acetohydroxyacid synthase
  931. Effects of DPP‐4 inhibitors, GLP‐1 receptor agonists, SGLT‐2 inhibitors, and sulfonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: a …
  932. Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review
  933. Studies of binding by sulfonylureas with glyoxal-and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns
  934. Comment on Dawed et al. Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas. Diabetes Care 2021; 44: 2673 …
  935. Position of sulfonylureas in the current ERA: Review of national and international guidelines
  936. Association of sulfonylureas with the risk of dementia: A population‐based cohort study
  937. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP‐4 inhibitors: population‐based cohort study
  938. One-Pot Synthesis of Thio-Augmented Sulfonylureas via a Modified Bunte’s Reaction
  939. Is it time to ban sulfonylureas?
  940. Association of Renal and Cardiovascular Safety With DPP‐4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
  941. Synthesis, herbicidal activity and soil degradation of novel 5‐substituted sulfonylureas as AHAS inhibitors
  942. Characterization of Binding by Sulfonylureas with Normal or Modified Human Serum Albumin using Affinity Microcolumns Prepared by Entrapment
  943. Comparative safety of sulfonylureas among US nursing home residents
  944. A potential role of calpains in sulfonylureas (SUs)–mediated death of human pancreatic cancer cells (1.2 B4)
  945. An Ultrasensitive Lateral Flow Immunoassay Based on Metal-Organic Framework-Decorated Polydopamine for Multiple Sulfonylureas Adulteration in Functional …
  946. Structure–Stability Relationship of NLRP3 Inflammasome-Inhibiting Sulfonylureas
  947. Sulfonylureas and metformin were not associated with an increased rate of serious bleeding in warfarin users: a self‐controlled case series study
  948. … to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021; 44 …
  949. COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
  950. Outcomes in patients with aneurysmal subarachnoid hemorrhage receiving sulfonylureas: a propensity-adjusted analysis
  951. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis
  952. Risk of severe hypoglycemic events from amiodarone‐sulfonylureas interactions: a population‐based nested case‐control study
  953. A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients
  954. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort …
  955. Effect of berberine on in vitro metabolism of sulfonylureas: A herb–drug interactions study
  957. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants
  958. Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study
  959. A molecularly imprinted polymer for microextraction by packed sorbent of sulfonylureas herbicides from corn samples
  960. Chemical preparation, degradation analysis, computational docking and biological activities of novel sulfonylureas with 2, 5-disubstituted groups
  961. Dynamics of total volume of pancreatic α‐and β‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
  962. Efficacy and cardiovascular safety of sulfonylureas
  963. Cost-Utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in Indian healthcare payer’s perspective
  964. Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study
  965. Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study
  966. The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
  967. Effects of Co‐administration of Sulfonylureas and Antimicrobial Drugs on Hypoglycemia in Patients with Type 2 Diabetes Using a Case‐Crossover Design
  968. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
  969. Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
  970. Adding Sodium–Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized …
  971. 125-LB: Individualized Cost-Effectiveness Assessment of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Sulfonylureas as Add-On Therapy in People with …
  972. Cardiac mitoKATP channel high-affinity sulfonylureas were associated with an increased MACE risk compared with low-affinity sulfonylureas in a nationwide …
  973. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase‐4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients
  974. Effects of Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas on Cognitive and Physical Function in Nursing Home Residents
  975. Effects of Remote Ischemic Preconditioning on Decreasing Troponin Release in Patients Not Taking Sulfonylureas After Cardiac Surgery–A Meta-Analysis
  976. Clinical review: Safety and efficacy comparison between sulfonylureas and dipeptidyl peptidase-4 inhibitors as second-line therapies in type 2 diabetes mellitus
  977. Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective …
  978. Adherence to Sulfonylureas in Comparison to Metformin among T2DM Patients: A Systematic Review and Meta-Analysis
  979. Sulfonylureas in the treatment of type 2 diabetes mellitus: a fresh look and new insights
  980. In Reply—Comparison of Outcomes With Metformin and Sulfonylureas in Chronic Kidney Disease
  981. KCNQ1 rs2237895 polymorphism is associated with the therapeutic response to sulfonylureas in Iranian type 2 diabetes mellitus patients
  982. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel
  983. Sulfonylureas and Meglitinides
  984. The residual effect of metsulfuron on soybean tolerant and non-tolerant to sulfonylureas
  985. Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus
  986. The place of sulfonylureas in the evolving landscape of combination therapy
  987. Hypoglycemia with insulin and sulfonylureas
  988. Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID …
  989. Concomitant use of sulfonylureas and beta-blockers and the risk of severe hypoglycemia: Population-based cohort study
  990. Dynamics of total volume of pancreatic α‐and β‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
  991. FC 125: Comparative Effectiveness of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylureas in Addition to Metformin: A Population-Based Cohort Study of Patients …
  992. Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus
  993. Comparative toxicological analysis of metformin (Biguanide) and glibenclamide (Sulfonylureas), using zebrafish embryotoxicity test (ZFET)
  994. Sulfonylureas target the neurovascular response to decrease Alzheimer’s pathology
  995. Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction
  996. Risk of cardiovascular outcomes in type 2 diabetes patients following addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-IRA therapy
  997. In silico screening for inhibitory potentiality towards protein structure tyrosine phosphatase 1B of sulfonylureas derivatives
  998. Metformin and Other Sulfonylureas for Glycemic Control in Type 2 Diabetic Patients at a Tertiary Care Hospital in Jammu & Kashmir
  999. Effects of Sulfonylureas Treatment on Apoptosis, Total Superoxide Dismutase activity and Some Biochemical Parameters in Type 2 Diabetic Patients.
  1000. Can Sulfonylureas for Agricultural Use Cause Diabetes? A Report of Three Cases
  1001. We studied all 24 individuals with ABCC8-PNDM diagnosed in the UK, Italy, France, and US known to transfer from insulin to sulfonylureas before May 2010 …
  1002. Effect of herbal drug supplementation in pharmacokinetics and pharmacodynamics of sulfonylureas.
  1003. Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study
  1004. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes—Reply
  1005. … safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 …
  1006. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
  1007. Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort …
  1008. … -P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People …
  1009. Determination of the ionization constants of sulfonylureas in THF–water media by potentiometric titration and RPLC methods
  1010. RWD89 Risk of Electrolyte Imbalance in Elderly Colorectal Cancer Patients Following Treatment with Metformin Vs Sulfonylureas
  1011. Investigation of concomitant use of Alzheimer’s disease drugs with sulfonylureas and serious hypoglycemia
  1012. EPH3 Comparing Cardiac Safety Profile of Metformin and Sulfonylureas in Colorectal Cancer (CRC) Patients with Type 2 Diabetes Mellitus (T2DM): Surveillance …
  1013. Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas: The Price of Prevention
  1014. 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
  1015. Comparison of Outcomes With Metformin and Sulfonylureas in Chronic Kidney Disease
  1016. RWD116 Hospitalizations Among Patients with Both Colorectal Cancer and Type II Diabetes Mellitus Treated with Metformin Vs. Sulfonylureas: A Seer-Medicare …
  1017. Sulfonylureas and the Risk of Ventricular Arrhythmias Among Patients with Type 2 Diabetes
  1018. High Concurrent Use of Sulfonylureas and Antimicrobials With Drug Interactions Causing Hypoglycemia
  1019. Computational studies sulfonylureas molecules
  1020. Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical …
  1021. “Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care”
  1022. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021; 44: 2673–2682
  1023. Comparison of Efficacy of Dipeptidyl Peptidase-4-Inhibitor Versus Sulfonylureas in Type 2 Diabetes Patients Inadequately Controlled with Metformin; A …
  1024. Response to Letter to the Editor:“Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care”
  1025. 1136-P: A Population-Based Assessment of the Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and Peptidomimetic Dipeptidyl Peptidase-4 …
  1026. Comparison of Safety and Economic Burden of Dipeptidyl Peptidase-4-Inhibitor Versus Sulfonylureas in Type 2 Diabetes Patients Inadequately Controlled with …
  1027. 302 Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients with Diabetes on Sulfonylureas: A Propensity Match Analysis
  1028. Sulfonylureas and Mortality Risk
  1029. … endocrine cells ratio in the pancreas of rats with type 2 diabetes mellitus following long-term therapy with incretin mimetics and their combination with sulfonylureas …
  1030. Second-generation Sulfonylureas
  1031. … Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
  1032. Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin …
  1033. Molecular Docking of Sulfonylureas to the SUR1 Receptor
  1034. A Review on Drug Related Problems in Type 2 DM with Combination of Sulfonylureas and Biguanides
  1035. … Neonatal Diabetes Mellitus (NDM) in Two Siblings Who Also Carry a Second Inactivating Mutation: Genetic Testing Allows for Improved Treatment With Sulfonylureas …
  1036. Effects of sulfonylureas, α-endosulfine counterparts, on Effects of sulfonylureas,-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of …
  1037. THE EFFECT OF SULFONYLUREAS DRUGS ON KIDNEY AND LIVER FUNCTIONS IN TYPE 2 DIABETIC PATIENTS
  1038. 2209-PUB: Factors Associated with Switching from Sulfonylureas (SUs) to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) among Individuals with Type 2 Diabetes in the …
  1039. Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene SLCO1B1 and Statins as Modifiers of Glycemic Response to Sulfonylureas
  1040. 1976-P: Cardiovascular Safety of Sulfonylureas in Type 2 Diabetes: Effect Modification by Obesity?
  1041. Simultaneous determination of three sulfonylureas herbicides froms environmental samples by HPLC-DAD
  1042. 1414-P: Characteristics Associated with Sulfonylureas and Basal Insulin Use following Metformin in Older Adults
  1043. Hospitalizations for Heart Failure Among Patients With Reduced Renal Function Treated With Metformin or Sulfonylureas: A Retrospective Cohort Study
Related Posts

Adipocyte Apoptosis (Killing Fat Cells)

(Sirt1 | Sirt 1) (Activator | Activators | Activation)

Glp 1 Agonist

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping